Allogenic bone marrow transplantation with fludarabine/busulfan16 conditioning regimen and dasatinib maintenance therapy for elderly Philadelphia-positive acute/advanced leukemia patients.
暂无分享，去创建一个
M. Taniwaki | S. Horiike | J. Kuroda | Y. Tsutsumi | Y. Shimura | N. Sasaki | M. Ohshiro | H. Uchiyama | C. Shimazaki | Yosuke Matsumoto | Mio Yamamoto | Tsutomu Kobayashi | S. Mizutani
[1] S. Kamel‐Reid,et al. Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia , 2009, Haematologica.
[2] S. Mustjoki,et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy , 2008, Leukemia.
[3] A. Nagler,et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity , 2006, Leukemia.
[4] G. Gahrton,et al. Bone marrow transplantation for chronic myeloid leukemia: long-term results. Chronic Leukemia Working Party of the European Group for Bone Marrow Transplantation. , 1993, Bone marrow transplantation.